Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.

Gretchen L SnyderPeng LiTerry MartinLei ZhangWei YaoHailin ZhengDavid R MaguireLisa R GerakKimberly E VanoverCharles P FranceRobert Davis

Published in: Psychopharmacology (2024)

receptor antagonist, as well a biased MOP receptor partial agonist with low intrinsic efficacy. ITI-333 mitigates opioid withdrawal/reinstatement, supporting its potential utility as a treatment for OUD.

Keyphrases

pain management
combination therapy
radiation therapy
binding protein
smoking cessation